Co-Authors
This is a "connection" page, showing publications co-authored by PADMANEE SHARMA and SANGEETA GOSWAMI.
Connection Strength
7.127
-
Myeloid-specific KDM6B inhibition sensitizes glioblastoma to PD1 blockade. Nat Cancer. 2023 Oct; 4(10):1455-1473.
Score: 0.957
-
Myeloid cell-targeted therapies for solid tumours. Nat Rev Immunol. 2023 02; 23(2):106-120.
Score: 0.880
-
A composite T?cell biomarker in pre-treatment blood samples correlates with detection of immune-related adverse events. Cancer Cell. 2022 03 14; 40(3):249-251.
Score: 0.865
-
ARID1A mutation plus CXCL13 expression act as combinatorial biomarkers to predict responses to immune checkpoint therapy in mUCC. Sci Transl Med. 2020 06 17; 12(548).
Score: 0.766
-
Immune profiling of human tumors identifies CD73 as a combinatorial target in glioblastoma. Nat Med. 2020 01; 26(1):39-46.
Score: 0.741
-
Modulation of EZH2 expression in T cells improves efficacy of anti-CTLA-4 therapy. J Clin Invest. 2018 08 31; 128(9):3813-3818.
Score: 0.673
-
A potential biomarker for anti-PD-1 immunotherapy. Nat Med. 2018 02 07; 24(2):123-124.
Score: 0.651
-
Genetic biomarker for cancer immunotherapy. Science. 2017 07 28; 357(6349):358.
Score: 0.627
-
Immune checkpoint therapy-current perspectives and future directions. Cell. 2023 04 13; 186(8):1652-1669.
Score: 0.233
-
The Next Decade of Immune Checkpoint Therapy. Cancer Discov. 2021 04; 11(4):838-857.
Score: 0.202
-
Neoadjuvant PD-L1 plus CTLA-4 blockade in patients with cisplatin-ineligible operable high-risk urothelial carcinoma. Nat Med. 2020 12; 26(12):1845-1851.
Score: 0.196
-
Blockade of CTLA-4 and PD-1 Enhances Adoptive T-cell Therapy Efficacy in an ICOS-Mediated Manner. Cancer Immunol Res. 2019 Nov; 7(11):1803-1812.
Score: 0.181
-
A phase 1-2 trial of sitravatinib and nivolumab in clear cell renal cell carcinoma following progression on antiangiogenic therapy. Sci Transl Med. 2022 04 20; 14(641):eabm6420.
Score: 0.054
-
Durable responses in patients with genitourinary cancers following immune checkpoint therapy rechallenge after moderate-to-severe immune-related adverse events. J Immunother Cancer. 2021 07; 9(7).
Score: 0.051
-
Outcomes of patients with metastatic renal cell carcinoma with sarcomatoid dedifferentiation to immune checkpoint inhibitors. Urol Oncol. 2021 02; 39(2):134.e9-134.e16.
Score: 0.049